Abstract
Overview
Introduction
In 2007, the market value of HRT for menopausal symptoms saw its first upturn
since the Women' s Health initiative (WHI) study results in 2002; highly
publicized findings which linked HRT to cancer and cardiovascular safety
risks. The recent growth of the market is due in part to the increasing price
of HRT products but can only be sustained by a similar increase in volume
sales.
Scope
- Analysis of patient potential, unmet needs, market dynamics, and clinical
trial design in HRT, supported by opinion leader comment.
- Assessment of pipeline drugs and future treatment trends and their impact
on prescribing patterns and behavior.
- Sales based market forecasts to 2017, providing a breakdown by
dose-strength, marketed brands and pipeline drugs, drug class and region.
- A review of the opportunities and threats facing HRT manufacturers in the
seven major markets.
Report Highlights
The market growth seen from 2006 to 2007 will be maintained by a growing
number of women requesting pharmaceutical treatment for their menopausal
symptoms in the next decade. The value of the seven major markets combined is
expected to grow by over $1 billion as volume sales increase by 0.5% and
innovative products set higher price points.
New mechanisms of action that prevent the agents from affecting breast and
uterine tissue should diminish safety concerns and revolutionize the HRT
market. Two late-stage pipeline products, Wyeth' s Aprela (bazedoxifene,
conjugated equine estrogen) and Bionovo' s MF-101 (liquiritigenin) are expected
to generate combined revenue of $893m in 2017.
Reactive strategies, such as the launch of alternatively delivered therapies
and low dose reformulations, were useful, short-term revenue generators in the
wake of the WHI publication. Now the market profile must be raised, and
physician/patient education used to maintain growth in the long term.
Reasons to Purchase
- Quantify the future size of the HRT market and the number of women
currently eligible for treatment for menopausal symptoms in the US, 5EU, and
Japan.
- Understand unmet needs, and opportunities/threats in the HRT market based
on key opinion leader comments.
- Benchmark key late-stage HRT compounds against current market leading
brands.
| 
View Cart
